Pharm Exec profiles its 2022 Emerging Pharma Leaders.
Click on the links below to read the profiles of Pharm Exec's 2022 Emerging Pharma Leaders.
Naveen Bazaj, Head of Corporate Development, Alector
Gardner Gendron, Chief/US Head of Commercial, NS Pharma
Aida Habtezion, MD, Senior VP, Chief Medical Officer, and Head of Worldwide Medical and Safety, Pfizer
Matthew J. Hawryluk, PhD, Executive VP, Chief Business Officer and Cambridge Site Head, Gritstone bio
Charmaine Lykins, Chief Commercial Officer, Karuna Therapeutics
Divya Chadha Manek, Senior Vice President of Clinical Development, Eyebiotech Limited (EyeBio)
Susan Pandya, MD, Vice President, Clinical Development, and Head of Cancer Metabolism Global Development Oncology and Immuno-Oncology, Servier Pharmaceuticals
Matthew R. Price, Co-Founder, Executive Vice President, Chief Operating Officer, and Board Director, Promontory Therapeutics
Quiona Russell, PhD, Associate Director of Medical Information and Medical Communication, G1 Therapeutics
Patricia Torr, US President and General Manager, Idorsia Pharmaceuticals
Shetal Vyas, Vice President of Operations, Ferring Pharmaceuticals
*From a pool of nominations, these final selections were judged in a blinded process by three Pharmaceutical Executive Editorial Advisory Board members and a former EPL. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with executives most likely to inhabit key “c-suite” functions.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.